Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ: ALNY )

245.44 +6.57 (+2.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is... 
Via Benzinga
Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit
Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit. 
Via Investor's Business Daily
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Analyzing Alnylam Pharmaceuticals's Unusual Options Activity
On Tuesday, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Planned CEO Leadership Transition
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
3 Growth Stocks Near 52-Week Highs to Buy Anyway
These top performers have what it takes to keep providing outsized gains for patient investors. 
Via The Motley Fool
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Where Alnylam Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
10 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option... 
Via Benzinga
Analyst Ratings For Alnylam Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
This Robot-Run Large Cap ETF Has Less Apple, Microsoft, Amazon, Facebook Compared To SPY And Is Bullish On These Manufacturing Stocks Instead
The Qraft AI-Enhanced US Large Cap ETF (NYSE:QRFT) has revea... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 100 stocks hit new 52-week highs. Things to Consider: The largest company by market cap to break to a new 52-week high was Pfizer (... 
Via Benzinga
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday
A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict. 
Via The Motley Fool
Why Is Dicerna Stock Getting Slammed Today?
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021
Upgrades For Meritage Homes Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.